The purpose of this study is to see if it is safe and effective to give one of three different triple-drug combinations to HIV-infected patients who have never been treated with anti-HIV drugs.

In this open-label, strategic study patients are evaluated at Weeks 0, 1, 2, 4, 8, 12 to Week 48 after being treated on one of the following regimens:

Stavudine (d4T) + Didanosine (ddI) + Lamivudine (3TC) or d4T + ddI + Indinavir or d4T + ddI + Nevirapine.

Inclusion Criteria

Patients must have:

• Diagnosed asymptomatic HIV infection.
• HIV-1 RNA greater than 500 copies/ml.
• CD4+ T-cell count greater than 200/mm3.
• Never received antiretroviral therapy.

Exclusion Criteria

Co-existing Condition:

Excluded:

Severe non-HIV-related disease.

Patients with the following prior conditions are excluded:

History of neuropathy.

Prior Medication:

Excluded:

• Investigational drug within 1 month prior to study.
• Immunomodulatory drug within 1 month prior to study.

Prior Treatment:

Excluded:

• Radiation therapy within past month.
• Chemotherapy within past month.